NCT06618287 2026-03-17
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
Bristol-Myers Squibb
Myeloid Therapeutics
University of Texas Southwestern Medical Center
The Netherlands Cancer Institute
The Netherlands Cancer Institute